Medicine and Dentistry
Plasma
100%
Assessment
100%
Betrixaban
94%
Assay
77%
Blood Clotting Factor 10a Inhibitor
70%
Apixaban
50%
Activated Protein C Resistance
50%
Low Molecular Weight Heparin
48%
Laboratory
44%
Direct Oral Anticoagulant
44%
Thrombophilia
44%
Diagnostic Test
44%
Woman
27%
Heparin
22%
Inpatient
18%
Patient
16%
Oral Contraceptive Agent
16%
Coagulation
16%
Interference
16%
Combination Therapy
14%
Fondaparinux
14%
Buffer
14%
Liquid Chromatography-Mass Spectrometry
11%
Rivaroxaban
11%
Measurement
11%
Protein S
11%
Dabigatran
11%
Prothrombinase
11%
Tandem Mass Spectrometry
11%
Activated Protein C
11%
Viper Venom
8%
Partial Thromboplastin Time
8%
Adaptation
7%
Donor
7%
Diagnostic Error
5%
Therapeutic Procedure
5%
Accuracy
5%
Protein C
5%
Absence
5%
Chemical Compound
5%
Lupus Anticoagulant
5%
Gestagen
5%
Protein C
5%
Antithrombin
5%
Man
5%
Edoxaban
5%
Blood Sampling
5%
Volunteer
5%
Liquid Chromatography
5%
Emergency
5%
Pharmacology, Toxicology and Pharmaceutical Science
Betrixaban
88%
Blood Clotting Factor 10a Inhibitor
79%
Direct Oral Anticoagulant
57%
Emergency
50%
Edoxaban
48%
Apixaban
48%
Low Molecular Weight Heparin
48%
Prothrombin
47%
Active Metabolite
44%
Thromboplastin
28%
Heparin
22%
Clotting Time
19%
Buffer
14%
Fondaparinux
14%
Fibrinolytic Agent
12%
Anticoagulant Agent
12%
Rivaroxaban
10%
Viper Venom
9%
Dabigatran
8%
Fenfluramine
7%
Daboia russellii
7%
Neuroscience
Edoxaban
88%
Heparin
51%
Blood Clotting Factor 10a
51%
Mass Spectrometry
48%
Chromatography
48%
Fondaparinux
29%
Low Molecular Weight Heparin
29%
Interference
14%
